Ho Of cial ReviewerdSCAI Content Reviewerd ACC NCDR Science and Quality Oversight Committee None None None None  Boston Scienti c* None Hani Jneid Content ReviewerdAHA None None None None None None Christopher M. Kramer Content Reviewerd ACC Appropriate Use Criteria Task Force  Synarc None None  Novartisy  Siemens None None Carl J. Lavie Jr. Organizational Reviewerd AACVPR  Abbott  Boehringer Ingelheim  GlaxoSmithKliney  P zery  Upsher Smith  Amarin*  AstraZeneca None None None None None Alice M. Mascette Organizational ReviewerdNHLBI None None None None None None Continued on the next page JACC Vol. 63, No. 7, 2014 Nallamothu et al. February 25, 2014:722 45 ACC/AHA/SCAI/AMA-PCPI/NCQA Appendix B. 